Should I buy or sell Jazz Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks .

What is Jazz Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $135.00 to $225.00. On average, they predict the company's stock price to reach $194.86 in the next year. This suggests a possible upside of 70.2% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts .

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 at the start of the year. Since then, JAZZ stock has decreased by 28.1% and is now trading at $114.49. View the best growth stocks for 2023 here .

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,570,000 shares, a decline of 6.2% from the October 31st total of 2,740,000 shares. Based on an average daily trading volume, of 644,000 shares, the short-interest ratio is presently 4.0 days. View Jazz Pharmaceuticals' Short Interest .

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our JAZZ earnings forecast .

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company had revenue of $838.12 million for the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a net margin of 2.11% and a trailing twelve-month return on equity of 22.23%. During the same period in the previous year, the company posted $3.86 EPS.

What ETFs hold Jazz Pharmaceuticals' stock?

ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE) , Amplify Seymour Cannabis ETF (CNBS) , AdvisorShares Pure Cannabis ETF (YOLO) , SPDR S&P Pharmaceuticals ETF (XPH) , VanEck Pharmaceutical ETF (PPH) , Invesco Pharmaceuticals ETF (PJP) , iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $18.15-$19.00 for the period, compared to the consensus earnings per share estimate of $18.66. The company issued revenue guidance of $3.75-$3.875 billion, compared to the consensus revenue estimate of $3.83 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com . Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND) , Gilead Sciences (GILD) , Alibaba Group (BABA) , Micron Technology (MU) , NVIDIA (NVDA) , Netflix (NFLX) , Tesla (TSLA) , AbbVie (ABBV) , Bank of America (BAC) and Biogen (biib) .

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (3.76%), JPMorgan Chase & Co. (2.26%), FMR LLC (2.12%), Ameriprise Financial Inc. (2.06%), Polaris Capital Management LLC (1.97%) and Morgan Stanley (1.30%). Insiders that own company stock include Anne Oriordan , Bruce C Cozadd, Bruce C Cozadd , Christopher J Tovey , Elmar Schnee , Finbar Larkin , James E Flynn, Jennifer E Cook , Kenneth W O'keefe , Kim Sablich , Mark Douglas Smith , Neena M Patil , Patricia Carr , Patrick G Enright , Peter Gray , Renee D Gala , Rick E Winningham , Robert Iannone and Samantha Pearce . View institutional ownership trends .

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion. Read More

Jazz Pharmaceuticals Stock Price, News & Analysis (NASDAQ:JAZZ)

$114.49

-3.05 (-2.59%)

(As of 11/28/2023 ET)

Compare

Today's Range: $111.25
▼
$117.21
50-Day Range: $114.49
▼
$136.00
52-Week Range: $111.25
▼
$160.96

Volume: 1.52 million shs
Average Volume: 715,410 shs
Market Capitalization: $7.21 billion

P/E Ratio: 130.10
Dividend Yield: N/A
Price Target: $194.86

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 70.2% Upside
$194.86 Price Target
Short Interest: Healthy
4.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: 0.33
Based on 7 Articles This Week
Insider Trading: Selling Shares
$236,748 Sold Last Quarter
Proj. Earnings Growth: 13.50%
From $15.41 to $17.49 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

116th out of 949 stocks

Pharmaceutical Preparations Industry

39th out of 440 stocks

3.4

Analyst's Opinion

Consensus Rating
Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $194.86, Jazz Pharmaceuticals has a forecasted upside of 70.2% from its current price of $114.49.
Amount of Analyst Coverage
Jazz Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.08% of the outstanding shares of Jazz Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Jazz Pharmaceuticals has recently decreased by 6.20%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Jazz Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Jazz Pharmaceuticals does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Jazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.
Environmental Sustainability
The Environmental Impact score for Jazz Pharmaceuticals is -1.96.

1.8

News and Social Media Coverage

News Sentiment
Jazz Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.
Search Interest
17 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $236,748.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.
Percentage Held by Institutions
88.15% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Jazz Pharmaceuticals are expected to grow by 13.50% in the coming year, from $15.41 to $17.49 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jazz Pharmaceuticals is 130.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 114.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jazz Pharmaceuticals is 130.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 99.68.
Price to Earnings Growth Ratio
Jazz Pharmaceuticals has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Jazz Pharmaceuticals has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JAZZ Stock News Headlines

November 28, 2023 | msn.com

UBS Downgrades Jazz Pharmaceuticals (JAZZ)

November 28, 2023 | americanbankingnews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded by UBS Group to "Neutral"

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 27, 2023 | uk.investing.com

Teva Pharma 'uniquely positioned,' Jazz Pharmaceuticals set-up balanced - UBS

November 27, 2023 | insidermonkey.com

5 Best Upside Stocks To Buy Now

November 14, 2023 | thetimes.co.uk

Jazz global licensing deal swings IP Group shares

November 14, 2023 | markets.businessinsider.com

IP Group: Autifony Signs Up To $770 Mln Worth Global Licencing Deal With Jazz Pharma

November 14, 2023 | msn.com

Jazz Pharma enters collaboration to develop neurological drugs

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 14, 2023 | finance.yahoo.com

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

November 10, 2023 | finance.yahoo.com

Is Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) ROE Of 2.3% Concerning?

November 9, 2023 | finance.yahoo.com

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2023 Earnings Call Transcript

November 8, 2023 | finance.yahoo.com

Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics

November 8, 2023 | seekingalpha.com

Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation

November 8, 2023 | finanznachrichten.de

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

November 8, 2023 | finance.yahoo.com

Jazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue Guidance

November 8, 2023 | finance.yahoo.com

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

November 8, 2023 | benzinga.com

Epilepsy Drugs Market Size Worth $10.70 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

November 7, 2023 | markets.businessinsider.com

Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 7, 2023 | finance.yahoo.com

Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key Metrics

November 7, 2023 | markets.businessinsider.com

Jazz Pharma, MD Anderson Collaborate To Evaluate Zanidatamab In HER2-Expressing Cancers

November 7, 2023 | finance.yahoo.com

Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers

November 1, 2023 | finanznachrichten.de

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

October 26, 2023 | benzinga.com

Advancing Neuroendocrine Tumor Treatment Pipeline: Comprehensive Insights into Clinical Trials by 55+ Key Companies by DelveInsight

October 25, 2023 | finance.yahoo.com

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023

October 23, 2023 | finance.yahoo.com

Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023

October 21, 2023 | msn.com

Jazz Pharma (NASDAQ:JAZZ) Evaluating Strategic Options

See More Headlines

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:JAZZ
CUSIP: G5087110
CIK: 1232524
Web: www.jazzpharma.com
Phone: (531) 634-7800
Fax: 353-1634-7850
Employees: 2,800
Year Founded: 2003

Price Target and Rating

Average Stock Price Target: $194.86
High Stock Price Target: $225.00
Low Stock Price Target: $135.00
Potential Upside/Downside: +70.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.88
Trailing P/E Ratio: 130.10
Forward P/E Ratio: 7.43
P/E Growth: 0.94
Net Income: $-224,060,000.00
Net Margins: 2.11%
Pretax Margin: -2.73%
Return on Equity: 22.23%
Return on Assets: 6.73%

Debt

Debt-to-Equity Ratio: 1.46
Current Ratio: 2.06
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: $3.66 billion
Price / Sales: 1.97
Cash Flow: $21.52 per share
Price / Cash Flow: 5.32
Book Value: $55.42 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 62,960,000
Free Float: 60,187,000
Market Cap: $7.21 billion
Optionable: Optionable
Beta: 0.73

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Bruce C. Cozadd (Age 59)
Co-Founder, Chairman & CEO
Comp: $2.45M
Ms. Renee D. Gala (Age 51)
President & COO
Comp: $1.13M
Mr. Daniel N. Swisher Jr. (Age 60)
Non-Executive Employee
Comp: $1.47M
Dr. Robert Iannone M.D. (Age 56)
Executive VP and Global Head of Research & Development
Comp: $1.08M
Ms. Kim Sablich M.B.A. (Age 54)
Executive VP & GM of US
Comp: $997.91k
Ms. Patricia Carr (Age 52)
Senior VP, CFO, & Chief Accounting Officer
Ms. Andrea N. Flynn Ph.D.
VP & Head of Investor Relations
Ms. Neena M. Patil J.D. (Age 47)
Executive VP & Chief Legal Officer
Comp: $331.61k
Dr. George Christopher Eliades Ph.D. (Age 52)
Senior VP of Corporate Development & Chief Transformation Officer
Ms. Heidi Manna (Age 52)
Senior VP & Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.
What is Jazz Pharmaceuticals' stock price target for 2024?: 8 equities research analysts have issued 12-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $135.00 to $225.00. On average, they predict the company's stock price to reach $194.86 in the next year. This suggests a possible upside of 70.2% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.
How have JAZZ shares performed in 2023?: Jazz Pharmaceuticals' stock was trading at $159.31 at the start of the year. Since then, JAZZ stock has decreased by 28.1% and is now trading at $114.49.
View the best growth stocks for 2023 here.
Are investors shorting Jazz Pharmaceuticals?: Jazz Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,570,000 shares, a decline of 6.2% from the October 31st total of 2,740,000 shares. Based on an average daily trading volume, of 644,000 shares, the short-interest ratio is presently 4.0 days.
View Jazz Pharmaceuticals' Short Interest.
When is Jazz Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our JAZZ earnings forecast.
How were Jazz Pharmaceuticals' earnings last quarter?: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company had revenue of $838.12 million for the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a net margin of 2.11% and a trailing twelve-month return on equity of 22.23%. During the same period in the previous year, the company posted $3.86 EPS.
What ETFs hold Jazz Pharmaceuticals' stock?: ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), Amplify Seymour Cannabis ETF (CNBS), AdvisorShares Pure Cannabis ETF (YOLO), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Pharmaceutical ETF (PPH), Invesco Pharmaceuticals ETF (PJP), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?: Jazz Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $18.15-$19.00 for the period, compared to the consensus earnings per share estimate of $18.66. The company issued revenue guidance of $3.75-$3.875 billion, compared to the consensus revenue estimate of $3.83 billion.
What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?: 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Jazz Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).
Who are Jazz Pharmaceuticals' major shareholders?: Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (3.76%), JPMorgan Chase & Co. (2.26%), FMR LLC (2.12%), Ameriprise Financial Inc. (2.06%), Polaris Capital Management LLC (1.97%) and Morgan Stanley (1.30%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends.
How do I buy shares of Jazz Pharmaceuticals?: Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Jazz Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More

This page (NASDAQ:JAZZ) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jazz Pharmaceuticals Stock Price, News & Analysis (NASDAQ:JAZZ)

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

JAZZ Stock Price History

JAZZ Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

JAZZ Stock Analysis - Frequently Asked Questions

Overall MarketRank^™